Work

Treatment with DC/AML Fusion Vaccine and CD3xCD123 Bi-Specific T-Cell Engager (CD123-CODV-TCE) for Treatment of Acute Myeloid Leukemia

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-148219

Authors: Dina Stroopinsky, Anita G. Koshy, Jessica J. Liegel, Myrna Nahas, Giulia Cheloni, Joshua Hauser, Daniela Torres, Poorva Bindal, Maryam Rahimian, Lina Bisharat, Paula Fraenkel, Ozlem Yildirim, Helene Bonnevaux, Stephane Guerif, Donald Kufe, Jacalyn Rosenblatt, David Avigan

Institutions: Beth Israel Deaconess Medical Center, Harvard University, Sanofi (France), Dana-Farber Cancer Institute

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3214503416

Cites:

Cited by: 1

Related to: 10